>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Clematichinenoside AR

Clematichinenoside AR

Catalog No.GC64524

클레마티키네노사이드 AR은 중국 전통 허브인 클레마티스 키넨시스(Clematis chinensis)에서 추출할 수 있는 주요 활성 성분으로 죽상동맥경화증(AS)을 비롯한 다양한 질병에 강력한 약리학적 효과가 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Clematichinenoside AR Chemical Structure

Cas No.: 761425-93-8

Size 가격 재고 수량
1 mg
US$207.00
재고 있음
5 mg
US$468.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Clematichinenoside AR is a major active ingredient that could be extracted from the traditional Chinese herb Clematis chinensis and has potent pharmacological effects on various diseases, including atherosclerosis (AS)[1].

Clematichinenoside AR alleviates foam cell formation and the inflammatory response in Ox-LDL-induced RAW264.7 cells by activating autophagy[1].

Clematichinenoside AR induces immunosuppression involving Treg cells in Peyer's patches of rats with adjuvant induced arthritis[2].

[1]. Yajing Diao, et al. Clematichinenoside AR Alleviates Foam Cell Formation and the Inflammatory Response in Ox-LDL-Induced RAW264.7 Cells by Activating Autophagy. Inflammation. 2021 Apr;44(2):758-768.
[2]. Ying Xiong, et al. Clematichinenoside AR induces immunosuppression involving Treg cells in Peyer's patches of rats with adjuvant induced arthritis. J Ethnopharmacol. 2014 Sep 11;155(2):1306-14.

리뷰

Review for Clematichinenoside AR

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Clematichinenoside AR

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.